Recent Updates
Recently added Catalysts
REPL Negative Sentiment

REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Replimune Group, Inc. Investors of Upcoming Deadline

Key Takeaway: Replimune Group, Inc. is involved in a securities fraud class action lawsuit initiated by Bernstein Liebhard LLP. The lawsuit affects investors who purchased shares between November 22, 2024, and July 21, 2025, and accuses the company of making false statements about the prospects of its drug RP1 in the IGNYTE trial. Investors may opt to join the lawsuit or remain absent class members, with the deadline for serving as lead plaintiff set for September 22, 2025. Bernstein Liebhard LLP represents the plaintiffs on a contingency fee basis.
Price reaction · baseline $5.71 (2025-09-17 close) · hit after-hours · 3 other REPL headline(s) in the window, move may be shared
day 0 close
-39.4%
day 1 · peak
-43.5%
day 3
-24.2%

Market Sentiment Analysis

CONCERNS & RISKS

  • Replimune Group is facing a securities fraud class action lawsuit.
  • The lawsuit alleges misrepresentations regarding the IGNYTE trial for RP1.
  • The lawsuit could lead to financial losses for shareholders if not resolved favorably.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+816%
120-day peak, hindsight
Typical move
25.1%
average across 6 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
RP1
Phase 2 · Non-Small Cell Lung Cancer (NSCLC)

Full Press Release Details

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Should You Join This Class Action Lawsuit?
Do you, or did you, own shares of Replimune Group, Inc. (NASDAQ: REPL)?
Did you purchase your shares between November 22, 2024 and July 21, 2025, inclusive?
Did you lose money in your investment in Replimune Group, Inc.?
If you purchased or acquired Replimune securities, and/or would like to discuss your legal rights and options please visit Replimune Group, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
A lawsuit was filed in the United States District Court for the District of Massachusetts on behalf of investors who purchased or acquired the securities of Replimune between November 22, 2024 and July 21, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.
Replimune’s lead drug product candidate is RP1, a cancer drug. According to the lawsuit, Defendants made misrepresentations concerning the IGNYTE trial’s prospects for RP1 in combination with nivolumab for the treatment of advanced melanoma.
If you wish to serve as lead plaintiff for the Class, you must file papers by September 22, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Frequently Asked Questions

What is the Replimune class action lawsuit about?

The lawsuit involves claims of securities fraud and misrepresentations about RP1’s IGNYTE trial.

When is the deadline to join the class action?

Individuals must file papers to serve as lead plaintiff by September 22, 2025.

Who is eligible to join the class action?

Shareholders who owned Replimune shares from November 22, 2024, to July 21, 2025.

What does it cost to participate in the lawsuit?

There are no fees or expenses for shareholders, as representation is on a contingency basis.

How can I get more information about the lawsuit?

Visit the Replimune Group, Inc. Shareholder Class Action Lawsuit page or contact Peter Allocco.

Last updated: Sep 18, 2025